Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Onyx Details Come Out, Amgen Turns To Biosimilars

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.

You may also be interested in...



Amgen Aims To Submit NDA for PCSK9 Candidate During “Data-Rich” 2014

The company now appears to be neck and neck with Regeneron in the race to market the first PCSK9 blocker for high cholesterol, with a filing possible by the end of the year. The drug is part of a deep late-stage pipeline, expected to yield pivotal data on numerous drugs by 2016.

Which Biosimilars Will Payers Cover? Manufacturer Pedigree Will Be A Factor

Large established firms will have an advantage in the competition for formulary position, payer survey finds.

Emerging Markets Earnings Roundup: Novartis, Amgen (Part 2)

Novartis executives trumpeted robust growth across most emerging markets, while cautioning a slowdown in China due to the industry-wide compliance probe. For Amgen, a play to expand internationally is said to be paying off though questions remain about its plans for Japan.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel